[go: up one dir, main page]

SG11201809857TA - Anti-CTLA-4 Antibodies - Google Patents

Anti-CTLA-4 Antibodies

Info

Publication number
SG11201809857TA
SG11201809857TA SG11201809857TA SG11201809857TA SG11201809857TA SG 11201809857T A SG11201809857T A SG 11201809857TA SG 11201809857T A SG11201809857T A SG 11201809857TA SG 11201809857T A SG11201809857T A SG 11201809857TA SG 11201809857T A SG11201809857T A SG 11201809857TA
Authority
SG
Singapore
Prior art keywords
seq
international
agency
research
science
Prior art date
Application number
SG11201809857TA
Inventor
Cheng-I Wang
Eve Ngoh
Siok Ping Yeo
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201809857TA publication Critical patent/SG11201809857TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 IIIIIIIIIIIIIIIIIII101110111101111011111111011111111111011111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/194265 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: (SG). YEO, Siok Ping; c/o Agency for Science Technology C07K 16/28 (2006.01) and Research, 8A Biomedical Grove 03-00, 138648 (SG). (21) International Application Number: (74) Agent: CLEGG, Richard et al.; Mewburn Ellis LLP, City PCT/EP2017/058956 Tower, 40 Basinghall Street, London Greater London EC2V (22) International Filing Date: 5DE (GB). 13 April 2017 (13.04.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 10201603721T 10 May 2016 (10.05.2016) SG KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, #20-10, Connexis 138632 (SG). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant or LS only): CLEGG, Richard Ian [GB/GB]; City Tower, 40 Basinghall Street, London Greater London (84) Designated States (unless otherwise indicated, for every EC2V 5DE (GB). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: WANG, Cheng-I; c/o Agency for Science UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Technology and Research, 8A Biomedical Grove 03-00, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 138648 (SG). NGOH, Eve; c/o Agency for Science Tech- EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = — = nology and Research, 8A Biomedical Grove 03-00, 138648 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (54) Title: Anti-CTLA-4 Antibodies = 2C8 clone DIQLTQSPSSVSASVGDRVTITCRATQG ISSWLAWYQQKPGKAPKLLIYAASSLQS = GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQANTLPLFTFGPGTKVDIK (SEQ ID NO: 1) = _ LC-CDR1: RATQGISSWLA (SEQ ID NO:5) = LC-CDR2: AASSLQS (SEQ ID NO:6) = LC-CDR3: QQANTLPLFT (SEQ ID NO:7) — = = = 2C8 gl clone = DIQMTQSPSSVSASVGDRVTITCRATQGISSWLAWYQQKPGKAPKLLIYAASSLQS = GVPSRFSGSGSGTDFTLTISSLOPEDFATYYCQQANTLPLFTFGPGTKVDIK (SEQ ID NO: 2) 1-1 LC-CDR1: RATQGISSWLA (SEQ ID NO:5) LC-CDR2: AASSLQS (SEQ ID NO:6) kr) LC-CDR3: QQANTLPLFT (SEQ ID NO:7) N 71' 0\ Il IN Figure 1 1-1 <= (57) : Anti-CTLA-4antibodies are disclosed. Also disclosed are compositions comprising such antibodies, and uses and meth- \" ods using the same. [Continued on next page] WO 2017/194265 Al MIDEDIM01101 DIDIRMEM1111111111111111111111111H1101111111111111111111 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201809857TA 2016-05-10 2017-04-13 Anti-CTLA-4 Antibodies SG11201809857TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201603721TA SG10201603721TA (en) 2016-05-10 2016-05-10 Anti-CTLA-4 Antibodies
PCT/EP2017/058956 WO2017194265A1 (en) 2016-05-10 2017-04-13 Anti-CTLA-4 Antibodies

Publications (1)

Publication Number Publication Date
SG11201809857TA true SG11201809857TA (en) 2018-12-28

Family

ID=58609383

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201603721TA SG10201603721TA (en) 2016-05-10 2016-05-10 Anti-CTLA-4 Antibodies
SG11201809857TA SG11201809857TA (en) 2016-05-10 2017-04-13 Anti-CTLA-4 Antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201603721TA SG10201603721TA (en) 2016-05-10 2016-05-10 Anti-CTLA-4 Antibodies

Country Status (10)

Country Link
US (2) US9758583B2 (en)
EP (1) EP3455255B1 (en)
JP (1) JP6650537B2 (en)
KR (1) KR20190015715A (en)
CN (1) CN109563165B (en)
AU (1) AU2017262448A1 (en)
CA (1) CA3023787A1 (en)
SG (2) SG10201603721TA (en)
TW (1) TW201739763A (en)
WO (1) WO2017194265A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2785692T (en) 2011-12-01 2018-01-04 Chemocentryx Inc Substituted anilines as ccr(4) antagonists
RU2017142352A (en) 2015-05-06 2019-06-06 Снипр Текнолоджиз Лимитед CHANGES IN MICROORGANISM POPULATIONS AND MODIFICATION OF MICROBIOTES
SI3303394T1 (en) 2015-05-29 2020-10-30 Agenus Inc. Anti-CTLA-4 antibodies and methods of their use
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
IL266918B2 (en) 2016-12-07 2024-03-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
CA3073984A1 (en) * 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4 antibodies and uses thereof
CN111954680B (en) 2017-11-10 2024-03-15 新加坡科技研究局 IL2Rβ/common gamma chain antibody
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019157533A1 (en) * 2018-02-12 2019-08-15 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP3796977A4 (en) * 2018-05-17 2022-03-02 The Board of Trustees of the Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
US11446289B2 (en) 2018-08-29 2022-09-20 Chemocentryx, Inc. Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
TW202039557A (en) 2018-11-09 2020-11-01 新加坡商優其洛伊生物私人有限公司 Il2rbeta/common gamma chain antibodies
WO2020094834A1 (en) 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
CN113614109A (en) 2018-12-21 2021-11-05 Ose免疫疗法公司 Bifunctional anti-PD-1/IL-7 molecules
CN119930820A (en) * 2018-12-27 2025-05-06 吉加根公司 Anti-CTLA-4 binding proteins and methods of use thereof
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN110343180B (en) * 2019-07-25 2021-03-30 北京免疫方舟医药科技有限公司 anti-CTLA-4 antibodies and uses thereof
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
CA3186777A1 (en) * 2020-06-11 2021-12-16 Nantbio, Inc. Anti-ctla4 monoclonal antibodies and chimeric antigen receptors
MX2022015948A (en) * 2020-07-02 2023-04-05 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof.
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022169269A1 (en) * 2021-02-03 2022-08-11 주식회사 유틸렉스 Anti-ctla-4 antibody and use thereof
RU2757418C1 (en) * 2021-03-04 2021-10-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный университет" Tetradecapeptide antagonist of interaction ctla-4 with b7-1
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2022214653A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2025137321A1 (en) * 2023-12-21 2025-06-26 Fenwal, Inc. System and method for affinity cell selection
EP4599843A1 (en) 2024-02-09 2025-08-13 Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau Car and modified cd200r combination
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0615451T3 (en) 1992-05-26 2006-04-24 Immunex Corp Hitherto unknown cytokine that binds to CD30
CN1371416B (en) 1999-08-24 2012-10-10 梅达里克斯公司 Human CTLA-4 antibody and its application
ITRM20010408A1 (en) 2001-07-10 2003-01-10 Univ Napoli Federico Ii CYTOTOXIC HUMAN MINI-ANTIBODY FOR CANCER CELLS THAT EXPRESS THE ERBB2 RECEPTOR.
KR100829283B1 (en) 2002-01-09 2008-05-13 메다렉스, 인코포레이티드 Human Monoclonal Antibodies against CD30
SI2511297T1 (en) 2004-02-06 2015-07-31 Morphosys Ag Anti-CD38 human antibodies and uses therefor
CN1997670B (en) 2004-07-01 2014-04-30 诺和诺德公司 Human anti-KIR antibodies
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human CD134 (OX40) human monoclonal antibody and method of making and using same
PT2511301T (en) 2006-08-04 2018-03-08 Medimmune Ltd Human antibodies to erbb 2
WO2008059491A1 (en) 2006-11-13 2008-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using sirna molecules directed against cd24
HRP20131113T1 (en) 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
CN101951959A (en) 2007-11-30 2011-01-19 百时美施贵宝公司 Anti-B7H4 monoclonal antibody-drug conjugate and using method
TWI729512B (en) 2008-12-09 2021-06-01 美商建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
CN102482701B (en) 2009-09-16 2015-05-13 免疫医疗公司 Class I Anti-CEA antibodies and uses thereof
NZ705128A (en) 2010-03-04 2015-04-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX2012013702A (en) 2010-05-26 2013-03-21 Univ Minnesota Single -chain variable fragment anti-cd133 antibodies and uses thereof.
EA031849B1 (en) 2010-08-23 2019-03-29 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Anti-ox40 antibodies and methods of using the same
AU2012248470B2 (en) 2011-04-25 2016-10-27 Daiichi Sankyo Company, Limited Anti-B7-H3 antibody
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
MX357391B (en) 2011-09-30 2018-07-06 Regeneron Pharma Anti-erbb3 antibodies and uses thereof.
ES2861435T3 (en) 2011-11-03 2021-10-06 Univ Pennsylvania Specific compositions of isolated B7-H4 and methods of using them
JP6368308B2 (en) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ VISTA modulators for cancer diagnosis and treatment
WO2014066532A1 (en) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
EP3508502B1 (en) 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
MY182431A (en) 2013-12-24 2021-01-25 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
CN104974253A (en) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 Anti-CTLA-4/PD-1 bispecific antibody as well as preparation method and application thereof
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies

Also Published As

Publication number Publication date
US20190153097A1 (en) 2019-05-23
US9758583B2 (en) 2017-09-12
CN109563165A (en) 2019-04-02
US11267887B2 (en) 2022-03-08
CN109563165B (en) 2020-09-25
JP2019519208A (en) 2019-07-11
TW201739763A (en) 2017-11-16
JP6650537B2 (en) 2020-02-19
US20170226211A1 (en) 2017-08-10
SG10201603721TA (en) 2017-12-28
KR20190015715A (en) 2019-02-14
EP3455255A1 (en) 2019-03-20
CA3023787A1 (en) 2017-11-16
WO2017194265A1 (en) 2017-11-16
AU2017262448A1 (en) 2019-01-03
EP3455255B1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201811184UA (en) Lag -3 binding members
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201909949XA (en) Targeted immunotolerance
SG11201810509PA (en) Anti-pd-l1 antibodies
SG11201906795SA (en) Novel plant cells, plants, and seeds
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201805493YA (en) Binding members with altered diversity scaffold domains
SG11201900634VA (en) Chimeric antigen receptor
SG11201811579VA (en) Chemiluminescent substrates
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201908472VA (en) Compositions and methods for activating nk cells
SG11201805001UA (en) Method of treating influenza a
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof